Literature DB >> 18302500

HMGB1 regulates RANKL-induced osteoclastogenesis in a manner dependent on RAGE.

Zheng Zhou1, Jun-Yan Han, Cai-Xia Xi, Jian-Xin Xie, Xu Feng, Cong-Yi Wang, Lin Mei, Wen-Cheng Xiong.   

Abstract

High-mobility group box 1 (HMGB1), a nonhistone nuclear protein, is released by macrophages into the extracellular milieu consequent to cellular activation. Extracellular HMGB1 has properties of a pro-inflammatory cytokine through its interaction with receptor for advanced glycation endproducts (RAGE) and/or toll-like receptors (TLR2 and TLR4). Although HMGB1 is highly expressed in macrophages and differentiating osteoclasts, its role in osteoclastogenesis remains largely unknown. In this report, we present evidence for a function of HMGB1 in this event. HMGB1 is released from macrophages in response to RANKL stimulation and is required for RANKL-induced osteoclastogenesis in vitro and in vivo. In addition, HMGB1, like other osteoclastogenic cytokines (e.g., TNFalpha), enhances RANKL-induced osteoclastogenesis in vivo and in vitro at subthreshold concentrations of RANKL, which alone would be insufficient. The role of HMGB1 in osteoclastogenesis is mediated, in large part, by its interaction with RAGE, an immunoglobin domain containing family receptor that plays an important role in osteoclast terminal differentiation and activation. HMGB1-RAGE signaling seems to be important in regulating actin cytoskeleton reorganization, thereby participating in RANKL-induced and integrin-dependent osteoclastogenesis. Taken together, these observations show a novel function of HMGB1 in osteoclastogenesis and provide a new link between inflammatory mechanisms and bone resorption.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18302500      PMCID: PMC2679382          DOI: 10.1359/jbmr.080234

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  42 in total

Review 1.  The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses.

Authors:  A M Schmidt; S D Yan; S F Yan; D M Stern
Journal:  J Clin Invest       Date:  2001-10       Impact factor: 14.808

2.  Characterization of a novel EGFP reporter mouse to monitor Cre recombination as demonstrated by a Tie2 Cre mouse line.

Authors:  R Constien; A Forde; B Liliensiek; H J Gröne; P Nawroth; G Hämmerling; B Arnold
Journal:  Genesis       Date:  2001-05       Impact factor: 2.487

Review 3.  Osteoclast differentiation and activation.

Authors:  William J Boyle; W Scott Simonet; David L Lacey
Journal:  Nature       Date:  2003-05-15       Impact factor: 49.962

4.  Mice lacking beta3 integrins are osteosclerotic because of dysfunctional osteoclasts.

Authors:  K P McHugh; K Hodivala-Dilke; M H Zheng; N Namba; J Lam; D Novack; X Feng; F P Ross; R O Hynes; S L Teitelbaum
Journal:  J Clin Invest       Date:  2000-02       Impact factor: 14.808

5.  A novel pathway of HMGB1-mediated inflammatory cell recruitment that requires Mac-1-integrin.

Authors:  Valeria V Orlova; Eun Young Choi; Changping Xie; Emmanouil Chavakis; Angelika Bierhaus; Eveliina Ihanus; Christie M Ballantyne; Carl G Gahmberg; Marco E Bianchi; Peter P Nawroth; Triantafyllos Chavakis
Journal:  EMBO J       Date:  2007-02-01       Impact factor: 11.598

6.  TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand.

Authors:  J Lam; S Takeshita; J E Barker; O Kanagawa; F P Ross; S L Teitelbaum
Journal:  J Clin Invest       Date:  2000-12       Impact factor: 14.808

7.  Distinct molecular mechanism for initiating TRAF6 signalling.

Authors:  Hong Ye; Joseph R Arron; Betty Lamothe; Maurizio Cirilli; Takashi Kobayashi; Nirupama K Shevde; Deena Segal; Oki K Dzivenu; Masha Vologodskaia; Mijung Yim; Khoi Du; Sujay Singh; J Wesley Pike; Bryant G Darnay; Yongwon Choi; Hao Wu
Journal:  Nature       Date:  2002-07-25       Impact factor: 49.962

8.  Release of chromatin protein HMGB1 by necrotic cells triggers inflammation.

Authors:  Paola Scaffidi; Tom Misteli; Marco E Bianchi
Journal:  Nature       Date:  2002-07-11       Impact factor: 49.962

9.  Regulation of osteoclast function and bone mass by RAGE.

Authors:  Zheng Zhou; David Immel; Cai-Xia Xi; Angelika Bierhaus; Xu Feng; Lin Mei; Peter Nawroth; David M Stern; Wen-Cheng Xiong
Journal:  J Exp Med       Date:  2006-04-10       Impact factor: 14.307

10.  A novel member of the leukocyte receptor complex regulates osteoclast differentiation.

Authors:  Nacksung Kim; Masamichi Takami; Jaerang Rho; Regis Josien; Yongwon Choi
Journal:  J Exp Med       Date:  2002-01-21       Impact factor: 14.307

View more
  54 in total

1.  PYK2 interacts with MyD88 and regulates MyD88-mediated NF-kappaB activation in macrophages.

Authors:  Cai-Xia Xi; Fei Xiong; Zheng Zhou; Lin Mei; Wen-Cheng Xiong
Journal:  J Leukoc Biol       Date:  2009-12-02       Impact factor: 4.962

2.  The complex relationship between bone remodeling and the physical and material properties of bone.

Authors:  D B Burr
Journal:  Osteoporos Int       Date:  2014-12-20       Impact factor: 4.507

Review 3.  Bone and the innate immune system.

Authors:  Julia F Charles; Mary C Nakamura
Journal:  Curr Osteoporos Rep       Date:  2014-03       Impact factor: 5.096

4.  Macrophage Migration Inhibitory Factor (MIF) Supports Homing of Osteoclast Precursors to Peripheral Osteolytic Lesions.

Authors:  Alexandru Movila; Takenobu Ishii; Abdullah Albassam; Wichaya Wisitrasameewong; Mohammed Howait; Tsuguno Yamaguchi; Montserrat Ruiz-Torruella; Laila Bahammam; Kazuaki Nishimura; Thomas Van Dyke; Toshihisa Kawai
Journal:  J Bone Miner Res       Date:  2016-06-02       Impact factor: 6.741

5.  Role of heme oxygenase-1 in postnatal differentiation of stem cells: a possible cross-talk with microRNAs.

Authors:  Magdalena Kozakowska; Krzysztof Szade; Jozef Dulak; Alicja Jozkowicz
Journal:  Antioxid Redox Signal       Date:  2014-01-30       Impact factor: 8.401

6.  Monoclonal anti-HMGB1 (high mobility group box chromosomal protein 1) antibody protection in two experimental arthritis models.

Authors:  Hanna Schierbeck; Peter Lundbäck; Karin Palmblad; Lena Klevenvall; Helena Erlandsson-Harris; Ulf Andersson; Lars Ottosson
Journal:  Mol Med       Date:  2011-06-07       Impact factor: 6.354

7.  RAGE supports parathyroid hormone-induced gains in femoral trabecular bone.

Authors:  Binu K Philip; Paul J Childress; Alexander G Robling; Aaron Heller; Peter P Nawroth; Angelika Bierhaus; Joseph P Bidwell
Journal:  Am J Physiol Endocrinol Metab       Date:  2009-12-22       Impact factor: 4.310

8.  Bone-targeting endogenous secretory receptor for advanced glycation end products rescues rheumatoid arthritis.

Authors:  Tatsuo Takahashi; Sayaka Katsuta; Yusuke Tamura; Nozomi Nagase; Keita Suzuki; Masaaki Nomura; Shunji Tomatsu; Ken-Ichi Miyamoto; Shinjiro Kobayashi
Journal:  Mol Med       Date:  2013-07-24       Impact factor: 6.354

9.  Osteosarcoma is characterised by reduced expression of markers of osteoclastogenesis and antigen presentation compared with normal bone.

Authors:  L Endo-Munoz; A Cumming; S Sommerville; I Dickinson; N A Saunders
Journal:  Br J Cancer       Date:  2010-06-15       Impact factor: 7.640

10.  The role of oxidative stress in aseptic loosening of total hip arthroplasties.

Authors:  Marla J Steinbeck; Lauren J Jablonowski; Javad Parvizi; Theresa A Freeman
Journal:  J Arthroplasty       Date:  2013-11-26       Impact factor: 4.757

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.